- Home
- CIA vs NBP Comparison
CIA vs NBP Comparison
Compare CIA & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIA | NBP |
|---|---|---|
| Founded | 1969 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.3M | 149.2M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CIA | NBP |
|---|---|---|
| Price | $3.45 | $1.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 104.7K | ★ 649.3K |
| Earning Date | 11-05-2026 | 08-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $255,616,000.00 | N/A |
| Revenue This Year | $0.22 | N/A |
| Revenue Next Year | $4.28 | N/A |
| P/E Ratio | $28.23 | ★ N/A |
| Revenue Growth | ★ 4.33 | N/A |
| 52 Week Low | $3.31 | $1.26 |
| 52 Week High | $6.54 | $5.19 |
Technical Indicators
Market Signals| Indicator | CIA | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 42.66 | 28.35 |
| Support Level | $3.39 | N/A |
| Resistance Level | $3.73 | $1.44 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 37.50 | 5.56 |
Price Performance
Historical ComparisonAbout CIA Citizens Inc. ($1.00 Par)
Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. The company operates in two business segments namely the Domestic Insurance and International Insurance segments.. The company majority generates revenues from Life Insurance segment. Company operates in USA, Columbia, Taiwan, Venezuela, Ecuador, Argentina, and Others.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.